Fig. 2.

SMPC levels are increased in patients with MVD but without type 2 diabetes. (a) SMPCs were identified within a monocyte gate based on forward and side scatter characteristics. Within the monocyte gate, CD14⁺ cells expressing CD105 were quantified based on the isotype (IgG1) control. (b) SMPC levels were similar between type 2 diabetic patients and healthy controls. c Within type 2 diabetic patients there were no differences in the SMPC frequencies between patients with and without MVD. (d) Within non-diabetic patients, individuals with MVD had 2.2-fold higher circulating SMPC levels compared with healthy controls. (e) Only the presence of PAD was associated with increased numbers of SMPCs compared with healthy controls (p < 0.01) and CAD (p < 0.05). Data are expressed as mean values ± SEM; *p < 0.05 and **p < 0.01 T2DM, type 2 diabetes mellitus